Penumbra, Inc. (PEN) News
Filter PEN News Items
PEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PEN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PEN News From Around the Web
Below are the latest news stories about PENUMBRA INC that investors may wish to consider to help them evaluate PEN as an investment opportunity.
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains?Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Reasons to Add Penumbra Stock to Your Portfolio NowPEN stays on investors' radars due to its strong Thrombectomy business and international growth plans. |
Capital Allocation Trends At Penumbra (NYSE:PEN) Aren't IdealWhat are the early trends we should look for to identify a stock that could multiply in value over the long term... |
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare ConferencePenumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. |
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes"Penumbra (PEN) could produce exceptional returns because of its solid growth attributes. |
Here's Why Penumbra (PEN) is a Strong Growth StockWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. |
Penumbra price target raised to $285 from $240 at TruistTruist raised the firm’s price target on Penumbra (PEN) to $285 from $240 and keeps a Buy rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, a |
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons WhyPenumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
Why Penumbra (PEN) is a Top Growth Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |